BIO:ON Insight #20 · Oct 13, 2026
Who pays first changes everything
Ono pays $80M upfront for Biohaven's IgG degraders with Japan, Korea and ASEAN rights, a Cochrane review links pharma perks to costlier prescribing, and hospitals sue to stop 340B rebates. This week's question: who pays first, and who gets paid later?
What I learned this week
What stuck with me after all three was the order, not the amounts. The same money carries different risk and different leverage depending on whether it goes first or arrives later. Next time you meet a big number, ask "who pays this, when, and on what conditions?" The headline gets much clearer. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Pipeline Analysis
Ono pays $80M upfront for Japan, Korea and ASEAN rights to Biohaven's IgG degraders
Ono PharmaceuticalBiohavenBHV-1300
- Market Trends
Cochrane review links pharma perks to costlier, less appropriate prescribing
- Market Trends
US hospitals sue to halt the 340B rebate pilot before its January start
US HHS / HRSA
AI summary
- 1Ono is paying Biohaven $80M upfront for Japan, Korea, Taiwan and ASEAN rights to three IgG degraders, led by Phase 3 Graves' candidate BHV-1300.
- 2A Cochrane review of 93 studies concluded that pharma payments and gifts increase inappropriate prescribing and probably raise costs.
- 3US hospitals sued to block the 340B rebate pilot, which would swap upfront discounts for rebates on 21 drugs from January 1.
Relevant rolesBDSales & marketingMarket access
Summary and tags generated by AI from the issue text.
References
- 1.
- 2.
- 3.Hospitals return to court to halt HHS's 340B rebate pilot before January launch (opens in a new tab)
Fierce Healthcare, Oct 9, 2026
Related insights
Other issues covering the same companies, drugs or topics